TABLE 2.
Characteristics of sequenced samples (n = 29).
| Sample ID | Age (years) | Sex | Date of sample collection | Place of sample collection | Recent travel history | Category | ϮClinical status | Assigned PANGO lineage | WHO label |
| Tanzania/KIDH-01B01/2021 | Unknown | Female | 23-January-21 | Dar es Salaam | Unknown | *Suspect | Symptomatic | B.1.351 | Beta |
| Tanzania/KIDH-01B03/2021 | Unknown | Female | 23-January-21 | Dar es Salaam | Unknown | *Suspect | Symptomatic | B.1.351 | Beta |
| Tanzania/KIDH-01B04/2021 | Unknown | Male | 23-January-21 | Dar es Salaam | Unknown | *Suspect | Symptomatic | B.1.351 | Beta |
| Tanzania/KIDH-01B06/2021 | Unknown | Male | 23-January-21 | Dar es Salaam | Unknown | *Suspect | Symptomatic | B.1.530 | – |
| Tanzania/KIDH-01B10/2021 | Unknown | Male | 23-January-21 | Dar es Salaam | Unknown | *Suspect | Symptomatic | B.1.351 | Beta |
| Tanzania/KIDH-02B01/2021 | Unknown | Unknown | 25-April-21 | Mwanza | Unknown | Suspect | Symptomatic | B.1.617.2 | Delta |
| Tanzania/KIDH-02B02/2021 | Unknown | Unknown | 26-April-21 | Dar es Salaam | Unknown | Traveler | Asymptomatic | B.1.351 | Beta |
| Tanzania/KIDH-02B04/2021 | Unknown | Unknown | 26-April-21 | Dar es Salaam | Unknown | Suspect | Asymptomatic | B.1.351 | Beta |
| Tanzania/KIDH-02B05/2021 | Unknown | Unknown | 22-April-21 | Dar es Salaam | Kenya | Traveler | Asymptomatic | B.1.351 | Beta |
| Tanzania/KIDH-02B06/2021 | Unknown | Unknown | 30-March-21 | Mwanza | Philippines | Traveler | Asymptomatic | B.1.351 | Beta |
| Tanzania/KIDH-02B07/2021 | Unknown | Unknown | 5-April-21 | Dar es Salaam | Unknown | Traveler | Asymptomatic | B.1.351 | Beta |
| Tanzania/KIDH-02B08/2021 | Unknown | Unknown | 12-April-21 | Dar es Salaam | Zambia | Traveler | Asymptomatic | B.1.351 | Beta |
| Tanzania/KIDH-02B09/2021 | 85 | Female | 10-April-21 | Kilimanjaro | Unknown | Suspect | Symptomatic | B.1.351 | Beta |
| Tanzania/KIDH-02B10/2021 | 45 | Male | 10-April-21 | Mwanza | India | Suspect | Symptomatic | B.1.351 | Beta |
| Tanzania/KIDH-02B11/2021 | 55 | Male | 10-April-21 | Mwanza | Unknown | Suspect | Symptomatic | B.1.525 | Eta |
| Tanzania/KIDH-02B12/2021 | 80 | Female | 11-April-21 | Kilimanjaro | Unknown | Suspect | Symptomatic | B.1.351 | Beta |
| Tanzania/KIDH-02B14/2021 | Unknown | Unknown | 3-May-21 | Dar es Salaam | India | #Traveler | Asymptomatic | B.1.617.2 | Delta |
| Tanzania/KIDH-02B15/2021 | Unknown | Unknown | 3-May-21 | Dar es Salaam | India | #Traveler | Asymptomatic | B.1.617.2 | Delta |
| Tanzania/KIDH-03B01/2021 | 39 | Male | 25-April-21 | Dar es Salaam | Unknown | Suspect | Symptomatic | B.1.351 | Beta |
| Tanzania/KIDH-03B03/2021 | Unknown | Unknown | 26-April-21 | Dar es Salaam | Unknown | Traveler | Asymptomatic | B.1.351 | Beta |
| Tanzania/KIDH-03B04/2021 | Unknown | Unknown | 26-April-21 | Dar es Salaam | Unknown | Traveler | Asymptomatic | B.1.351 | Beta |
| Tanzania/KIDH-03B05/2021 | 27 | Female | 22-April-21 | Mwanza | Unknown | Suspect | Symptomatic | B.1.617.2 | Delta |
| Tanzania/KIDH-03B07/2021 | 66 | Female | 23-April-21 | Mwanza | Unknown | Suspect | Symptomatic | B.1.351 | Beta |
| Tanzania/KIDH-03B10/2021 | 52 | Male | 30-March-21 | Arusha | Unknown | Suspect | Symptomatic | B.1.525 | Eta |
| Tanzania/KIDH-03B11/2021 | 46 | Female | 30-March-21 | Mtwara | Unknown | Suspect | Symptomatic | B.1.351 | Beta |
| Tanzania/KIDH-03B12/2021 | 60 | Male | 30-March-21 | Mwanza | Unknown | Suspect | Symptomatic | B.1.351 | Beta |
| Tanzania/KIDH-03B13/2021 | 58 | Male | 30-March-21 | Dar es Salaam | Unknown | Suspect | Symptomatic | B.1.351 | Beta |
| Tanzania/KIDH-03B14/2021 | Unknown | Unknown | 5-April-21 | Dar es Salaam | Unknown | Traveler | Asymptomatic | B.1.351 | Beta |
| Tanzania/KIDH-03B18/2021 | Unknown | Unknown | 11-April-21 | Mwanza | Unknown | Traveler | Asymptomatic | B.1.351 | Beta |
*The individuals were hospitalized in Dar es Salaam at different unknown dates. In the category column, all the travelers were outgoing except the two arriving from India indicated by #. ϮSymptomatic case was regarded as an individual who had tested positive for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) using nucleic acid amplification test with at least one of the following signs and/or symptoms; -fever, cough, tiredness, loss of taste or smell, sore throat, headache, aches and pains, diarrhea, a rash on skin, or discoloration of fingers or toes, red or irritated eyes, difficulty breathing or shortness of breath, loss of speech or mobility or confusion, chest pain. Whereas, asymptomatic cases were individuals who tested positive for SARS-CoV-2 using a nucleic acid amplification test but had no symptoms that were consistent with COVID-19 and were largely from travelers.